PlushCare, MD-Led Platform

PlushCare is a virtual primary care clinic founded in 2014 and acquired by Accolade Health in 2021, operating as one of the few telehealth platforms that genuinely functions as a full-service primary care provider rather than a condition-specific subscription service. The platform covers preventive care, chronic disease management, mental health, urgent care, and weight loss — and bills most of its services to insurance rather than charging patients a program fee. For GLP-1 weight loss, PlushCare prescribes only FDA-approved brand-name medications: Wegovy (semaglutide), Zepbound (tirzepatide), Ozempic, Mounjaro, Saxenda, Rybelsus, and Victoza. The company does not offer compounded GLP-1 options. Physicians follow standard clinical eligibility criteria — BMI of 30 or above, or 27 and above with a weight-related comorbidity — and require an initial lab workup and periodic monitoring labs as part of evidence-based obesity care. The insurance model is central to PlushCare''s proposition. The platform is in-network with major commercial insurers including Cigna, Humana, Aetna, Blue Cross Blue Shield, and UnitedHealthcare, with insured patients typically paying $30 per visit after insurance. Prior authorization for GLP-1 medications is handled by PlushCare''s care team. Without insurance coverage, brand-name GLP-1 medications can cost $1,000 or more per month — a significant consideration for self-pay patients who may be better served by compounding platforms. The $19.99/month membership fee provides platform access and booking capability; consultations are billed separately at $129 per visit for uninsured patients. A 30-day free trial is available. Lab costs for the initial GLP-1 evaluation typically add $100–$150 depending on the panel and insurance coverage for lab services. PlushCare fills a distinct niche: for insured patients who want a telehealth primary care physician to manage their GLP-1 treatment within the context of their broader health, rather than signing up for a separate weight-loss-specific platform, it provides the continuity and scope of a traditional primary care relationship at telehealth convenience and price. The platform covers preventive care, chronic disease management, mental health, urgent care, and weight loss — and bills most of its services to insurance rather than charging patients a program fee. For GLP-1 weight loss, PlushCare prescribes only FDA-approved brand-name medications: Wegovy (semaglutide), Zepbound (tirzepatide), Ozempic, Mounjaro, Saxenda, Rybelsus, and Victoza. The company does not offer compounded GLP-1 options. Physicians follow standard clinical eligibility criteria — BMI of 30 or above, or 27 and above with a weight-related comorbidity — and require an initial lab workup and periodic monitoring labs as part of evidence-based obesity care. The insurance model is central to PlushCare''s proposition. The platform is in-network with major commercial insurers including Cigna, Humana, Aetna, Blue Cross Blue Shield, and UnitedHealthcare, with insured patients typically paying $30 per visit after insurance. Prior authorization for GLP-1 medications is handled by PlushCare''s care team. Without insurance coverage, brand-name GLP-1 medications can cost $1,000 or more per month — a significant consideration for self-pay patients who may be better served by compounding platforms. The $19.99/month membership fee provides platform access and booking capability; consultations are billed separately at $129 per visit for uninsured patients. A 30-day free trial is available. Lab costs for the initial GLP-1 evaluation typically add $100–$150 depending on the panel and insurance coverage for lab services. PlushCare fills a distinct niche: for insured patients who want a telehealth primary care physician to manage their GLP-1 treatment within the context of their broader health, rather than signing up for a separate weight-loss-specific platform, it provides the continuity and scope of a traditional primary care relationship at telehealth convenience and price.